

Revision date: 17-Jan-2007 Version: 1.1 Page 1 of 5

### IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Ethacrynate Sodium Powder for Solution for Injection

Trade Name: Reomax Ampoules

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as diuretic.

### 2. COMPOSITION/INFORMATION ON INGREDIENTS

#### **Hazardous**

Ingredient	CAS Number	EU EINECS List	%
Ethacrynate Sodium	Not assigned	Not listed	5

Ingredient	CAS Number	<b>EU EINECS List</b>	%
Glucose	50-99-7	200-075-1	*
Mannitol	69-65-8	200-711-8	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

## 3. HAZARDS IDENTIFICATION

**Appearance:** Powder for reconstitution plus sterile diluent

Signal Word: WARNING

Statement of Hazard: Harmful if swallowed.

**Additional Hazard Information:** 

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver

(based on components) .

Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include loss of appetite

(anorexia), abdominal pain, changes in electrolytes, inability to swallow (dysphagia), nausea, vomiting, thirst, diarrhea. Clinical use has resulted in liver effects. Symptoms may include jaundice, liver function test abnormalities, and hepatitis. May cause adverse effects on the kidney. Other less common effects include allergic reaction, effects on hearing, vision.

Drowsiness, fatigue, or headache are also possible.

EU Indication of danger: Not classified

Material Name: Ethacrynate Sodium Powder for Solution for Page 2 of 5

Injection

Revision date: 17-Jan-2007 Version: 1.1

**Australian Hazard Classification** (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

> require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

## 4. FIRST AID MEASURES

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical

attention.

**Skin Contact:** Wash exposed area with soap and water, remove contaminated clothing and obtain medical

assistance if irritation occurs. This material may not be completely removed by conventional

laundering. Consult professional laundry service. Do not home launder.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:** May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride,

and other chlorine-containing compounds.

**Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

## 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

**Protections:** 

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

**Additional Consideration for Large** 

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Ethacrynate Sodium Powder for Solution for Page 3 of 5

Injection

Revision date: 17-Jan-2007 Version: 1.1

7. HANDLING AND STORAGE

General Handling: Avoid generating airborne dust. When handling, use proper personal protective equipment as

specified in Section 8.

**Storage Conditions:** Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

No Occupational Exposure Limit (OEL) or Short Term Exposure Limit (STEL) has been identified.

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.

**Personal Protective Equipment:** 

**Hands:** Chemical protective gloves **Eyes:** Safety glasses or goggles

**Skin:** Wear protective clothing when working with large quantities.

**Respiratory protection:** Respiratory protection is recommended as a precaution to minimize exposure when handling

this material in bulk.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Powder plus sterile diluent Color: Not applicable

Molecular Formula: Mixture Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

**Stability:** Stable under normal conditions of use. **Conditions to Avoid:** None for the normal use of this material

**Incompatible Materials:** Incompatible with acids.

11. TOXICOLOGICAL INFORMATION

**General Information:** The information in this section describes the potential hazards of the individual ingredients and

the formulation.

**Repeated Dose Toxicity** 

DurationSpeciesRouteDose (mg/kg/day)End PointTarget Organ(s)6 Month(s)MouseOral10 mg/kgNOAELNone identified

Acute Toxicity: (Species, Route, End Point, Dose)

**Mannitol** 

Rat Oral LD 50 13500 mg/kg Mouse Oral LD 50 22 g/kg

Glucose

Rat Oral LD50 25800 mg/kg

Page 4 of 5

Material Name: Ethacrynate Sodium Powder for Solution for

Injection

Revision date: 17-Jan-2007 Version: 1.1

**Ethacrynate Sodium** 

Mouse Oral LD 50 627 Rat Oral LD 50 1000 Mouse IV LD50 175 Rat IP LD50 43

Guinea pig Intravenous Maximally Symptomatic Dose 80

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

**Ethacrynate Sodium** 

21 Day(s) Mouse Oral 100 mg/kg/day LOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

**Ethacrynate Sodium** 

Embryo / Fetal Development Rat No route specified 100 mg/kg/day mg/kg NOAEL Not teratogenic

Fertility and Embryonic Development Rat No route specified 20 mg/kg/day NOAEL No effects at maximum dose Fertility and Embryonic Development Dog No route specified 5 mg/kg/day NOAEL No effects at maximum dose

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Ethacrynate Sodium** 

79 Week(s) Rat No route specified 45 times human dose NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be

avoided.

13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

Material Name: Ethacrynate Sodium Powder for Solution for Page 5 of 5

Injection

Revision date: 17-Jan-2007 Version: 1.1

**OSHA Label:** 

**WARNING** 

Harmful if swallowed.

#### Canada - WHMIS: Classifications

#### WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

#### **Glucose**

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

200-075-1

#### **Mannitol**

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
200-711-8

# 16. OTHER INFORMATION

Reasons for Revision: Updated Section 10 - Stability and Reactivity.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

**End of Safety Data Sheet**